InvestorsHub Logo
Followers 58
Posts 10321
Boards Moderated 1
Alias Born 09/21/2016

Re: XenaLives post# 194784

Thursday, 05/30/2019 8:12:53 AM

Thursday, May 30, 2019 8:12:53 AM

Post# of 470038

I agree with this speculation and add the speculation that the Aussies want the data on the same biomarkers for population screening tools.



https://www.fda.gov/files/drugs/published/Electronic-Technologies-in-Clinical-Trials---2.pdf
Pay particular attention to slides 18-24.

We have already seen evidence that AVXL trials have generated more information-data than what is required/described by basic trial criteria. So, as long as additional data gathering does not interfere w/trial protocols-information gathering then it is allowed. Gathering todays trial data by inference and correlations/interviews and picture(MRI) over time has less scientific value than direct data and real time measurements. IMO, unless how trials are done changes, we will never escape the CNS disease forest.

Based on the FDA paper attached it would seem they are in the same place.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News